--- title: "Rallybio CFO Jonathan Lieber moves to part-time employment" url: "https://aibio.space/news/rallybio-cfo-jonathan-lieber-moves-part-time-employment/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-09-09" section: "Company Updates" tickers: "NASDAQ:RLYB" source: "https://www.sec.gov/Archives/edgar/data/1739410/000119312526386511/d96849d8k.htm" summary: "Rallybio said Jonathan Lieber will move to part-time employment on September 15, 2026 and remain Chief Financial Officer. His employment ends at the closin" --- By the aibio.space news desk. Sources - [Rallybio Corporation 8-K (2026-09-09)](https://www.sec.gov/Archives/edgar/data/1739410/000119312526386511/d96849d8k.htm) - [Rallybio Corporation 10-K (2026-03-16): business](https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/rlyb-20251231.htm) - [Rallybio Corporation financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/) [RLYB](https://aibio.space/companies/rallybio/) 2026-09-09 # Rallybio CFO Jonathan Lieber moves to part-time employment Tickers [RLYB](https://aibio.space/companies/rallybio/) Rallybio said Jonathan Lieber will move to part-time employment on September 15, 2026 and remain Chief Financial Officer. His employment ends at the closing of the pending Avenzo Therapeutics merger. ## Key facts - **Company**: Rallybio Corporation (NASDAQ: RLYB) - **News type**: Company Updates - **Primary source**: [Rallybio Corporation 8-K (2026-09-09)](https://www.sec.gov/Archives/edgar/data/1739410/000119312526386511/d96849d8k.htm) *An inverted microscope in use. Public domain, via Wikimedia Commons. The picture shows the field, not the companies named.* Rallybio Corporation (NASDAQ: [RLYB](https://aibio.space/companies/rallybio/)) said in a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1739410/000119312526386511/d96849d8k.htm) dated September 8, 2026 that Jonathan Lieber, its Chief Financial Officer, will transition to part-time employment effective September 15, 2026. Lieber will remain Chief Financial Officer and Principal Financial Officer, with the same duties and authority after the transition, the filing says. The cover page of the 8-K lists Rallybio's common stock, par value $0.0001 per share, as trading on the NASDAQ Capital Market under the symbol RLYB, and checks the box identifying Rallybio as an emerging growth company. ## The employment side letter Lieber entered into an employment side letter with Rallybio and Rallybio, LLC, dated September 8, 2026. Under the letter, after the transition date he will receive a base salary of $420,000 and may participate in Rallybio's benefit plans. He will not be entitled to an annual bonus for 2026 or for any later year in which he is employed. Lieber's employment will terminate upon the closing of Rallybio's pending business combination with Avenzo Therapeutics, Inc., under the Agreement and Plan of Merger and Reorganization dated May 31, 2026, unless he or Rallybio ends it earlier. When his employment terminates, Lieber will receive severance payments under his employment agreement with Rallybio dated February 1, 2023, and a second amendment to that agreement. The filing says both documents were filed as exhibits to earlier reports. The side letter itself is Exhibit 10.1 to the 8-K, and the signature block, dated September 9, 2026, is signed by Lieber as Chief Financial Officer. ## The pending merger and the business The company's annual report on Form 10-K, filed March 16, 2026, describes Rallybio as a clinical-stage biotechnology company with a mission to develop and commercialize therapies for patients with severe and rare diseases. Its lead program, RLYB116, is a complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The annual report notes that the complement system plays a central role in innate immunity and also shapes the adaptive immune response. RLYB332, a long-acting matriptase-2 antibody for diseases of iron overload, is in preclinical development. The annual report describes a merger agreement signed March 1, 2026 with Candid, a clinical-stage biotechnology company advancing T-cell engager therapies for autoimmune diseases. The annual report says that merger was intended to qualify as a tax-free reorganization for U.S. federal income tax purposes. The pending business combination named in the 8-K is the Avenzo agreement dated May 31, 2026. The annual report describes a concurrent financing with investors committed to approximately $505.5 million in Candid common stock. ## The financial position The annual report's financial data, for the fiscal years ended December 31, 2025 and December 31, 2024, show revenue of $858,000 for 2025, compared with $636,000 for 2024. Research and development expense was $19.6 million in 2025 and $41.5 million in 2024. Rallybio reported a net loss of $9.0 million for 2025 and $57.8 million for 2024. Operating activities used $29.8 million of cash in 2025 and $49.3 million in 2024. At the end of 2024, cash and cash equivalents were $13.9 million and short-term investments were $51.6 million. ## What comes next The change cuts the finance chief's role to part-time while the company is mid-merger, and the filing gives no reason for it. Lieber gets no bonus after the transition and severance when he leaves, but the filing does not state the severance amount. Rallybio still reported a net loss of $9.0 million for 2025 and used $29.8 million of cash in operations, and the Avenzo merger is not yet closed. The filing ties the end of Lieber's employment to the closing of the Avenzo merger. The 8-K does not give a closing date for the Avenzo merger, and it does not name a successor or describe any change to the finance function beyond Lieber's part-time role. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story RLYB Rallybio Corporation NASDAQ ยท United States Open the starter desk ## More in Company Updates Company Updates ### [PTC reports third-quarter 2026 revenue of $358 million and raises product guidance](https://aibio.space/news/ptc-reports-third-quarter-2026-revenue-358-million-raises-product/) Oct 29, 2026 Company Updates ### [Processa clears VT-7208 CSU IND and names a new executive chair](https://aibio.space/news/processa-clears-vt-7208-csu-ind-names-new-executive-chair/) Oct 29, 2026 Company Updates ### [Kiora in-licenses late-stage KIO-401 for retinal artery occlusion](https://aibio.space/news/kiora-licenses-late-stage-kio-401-retinal-artery-occlusion/) Oct 29, 2026 --- Source page: https://aibio.space/news/rallybio-cfo-jonathan-lieber-moves-part-time-employment/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Rallybio CFO Jonathan Lieber moves to part-time employment", 2026-09-09, https://aibio.space/news/rallybio-cfo-jonathan-lieber-moves-part-time-employment/